skip navigation

Skip Nav

Ensayos clínicos

Ensayos clínicos

Women's Interagency HIV Study (WIHS)

Patrocinador(es) del estudio: National Institute of Allergy and Infectious Diseases (NIAID)
Números de identificación: NCT00000797, WIHS
  • Inscripciones abiertas

Propósito del estudio

The purpose of this study is to examine the impact of HIV infection in women with or at high risk for HIV infection. It will look at disease predictors, markers, and related trends.

Afección:
Infecciones por el VIH

Detalles del estudio

Participants have study visits once every 6 months. The data collected at each visit includes the following: medical and health history, obstetric/gynecological and contraceptive history, health care utilization, sexual behavior, usage of drugs and alcohol, psychosocial factors, sociodemographics, laboratory parameters, and physical and gynecological examination findings.Participants have study visits once every 6 months. The data collected at each visit includes the following: medical and health history, obstetric/gynecological and contraceptive history, health care utilization, sexual behavior, usage of drugs and alcohol, psychosocial factors, sociodemographics, laboratory parameters, and physical and gynecological examination findings.

Criterios de inclusión

    Women may be eligible for this study if they:
    • Are HIV infected or uninfected and at high risk for HIV.
    • Are willing to be retested for HIV infection for this study.
    • Are able to complete interview in English or Spanish.
    • Are able to travel to and from site clinic and participate in a baseline visit as an outpatient.
    • Are willing to have blood drawn.
    • Are at least 13 years of age.
    • Have consent of parent or guardian if under 18. Note: Patients must be 18 years of age for enrollment at certain sites.
    • These criteria apply to original recruits.
    This study has been reopened and the following criteria apply to women now enrolling: Women must meet all of the above criteria in addition to the following:
    • Have documented highly active antiretroviral therapy (HAART) and pre-HAART CD4 counts and HIV RNA quantification, if appropriate (i.e., HIV-positive, self-reported HAART).
    • Give consent to have their specimens stored in the WIHS national repository.
    • Note: If hardcopy documentation of a positive result from both an HIV ELISA test and a confirmatory Western blot are available, blood need not be drawn and women need not agree to be retested for HIV.

Criterios de exclusión

    Women will not be eligible for this study if they:
    • Acquired HIV perinatally.
    • Enrolled in the WIHS through another site.
    • Have AIDS-related conditions, if HIV-positive. If a woman reports an AIDS-related condition during screening that sites can refute through medical records, the woman is still eligible for enrollment.
    • This study has been reopened and the above criteria apply to women now enrolling.

Centros de estudio/contactos

California

    Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, 900331079, United States

             Yvonne Barranday, 323-343-8287

Inscripciones abiertas

    University of California - San Francisco, San Francisco, California, 94122, United States

             Claudia Ponath, 415-353-9797

Inscripciones abiertas

District of Columbia

    Georgetown Univ Med Ctr, Washington, District of Columbia, 20007, United States

             Emily Packard, 202-784-6472

Inscripciones abiertas

Illinois

    Chicago Consortium, Chicago, Illinois, 60612, United States

             Angie Shansky, 312-550-6192

Inscripciones abiertas

New York

    Montefiore Medical Center, Bronx, New York, 10467, United States

             Metta Cantlo, 718-655-8769

Inscripciones abiertas

    SUNY / Health Sciences Ctr at Brooklyn, Brooklyn, New York, 11203, United States

             Barbara Driscoll, 718-270-3310

Inscripciones abiertas

Actualizado: 18 de octubre del 2004

Volver arriba